The Covid vaccine has not only benefited thousands of people with normalcy in their lives but has also proven to be substantially beneficial to some pharmaceutical companies.
Analysts predicted an estimate of  $70bn to be the worth of the vaccine global market. Still, with the rise of the Delta variant of the coronavirus and the subsequent need for booster shots, this estimate is prone to a heightened increase.

The newly resurgent coronavirus is reckoned to cause 140,000 to 300,000 cases a day in the United States come August, fueled by the highly transmissible delta variant and the widespread resumption of normal activities, disease trackers predict.

Pfizer and Moderna reap a majority of the profits from the vaccine global market compared to their other counterparts, such as AstraZeneca, and Johnson & Johnson (J&J), who charge the respective governments a much more menial amount. The profit forecasts for Moderna and Pfizer are $19.2bn and $33.5bn, respectively, and Moderna anticipates that this estimate will increase considerably. The two companies have tweaked their mRNA vaccine to target the Delta variant and begin testing it on humans this month.